PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Purchased by Quantbot Technologies LP

Quantbot Technologies LP raised its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 102.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 39,019 shares of the company's stock after buying an additional 19,742 shares during the quarter. Quantbot Technologies LP owned approximately 0.07% of PROCEPT BioRobotics worth $3,142,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Raleigh Capital Management Inc. acquired a new position in shares of PROCEPT BioRobotics in the 4th quarter valued at $32,000. Signaturefd LLC increased its stake in PROCEPT BioRobotics by 26.7% in the fourth quarter. Signaturefd LLC now owns 689 shares of the company's stock valued at $55,000 after purchasing an additional 145 shares during the period. IFP Advisors Inc acquired a new position in PROCEPT BioRobotics in the fourth quarter valued at $58,000. Arcadia Investment Management Corp MI purchased a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at about $64,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of PROCEPT BioRobotics during the third quarter worth about $64,000. 89.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on PRCT shares. Truist Financial restated a "buy" rating and issued a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. Wells Fargo & Company restated an "overweight" rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Finally, Morgan Stanley decreased their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $94.29.

Insiders Place Their Bets

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the business's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the sale, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20. The trade was a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the transaction, the chief financial officer now owns 107,991 shares of the company's stock, valued at approximately $6,161,966.46. This represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,455 shares of company stock worth $368,322. 17.40% of the stock is owned by company insiders.

PROCEPT BioRobotics Price Performance

Shares of PRCT traded down $0.57 during mid-day trading on Thursday, hitting $61.76. The company's stock had a trading volume of 575,594 shares, compared to its average volume of 734,371. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a 1-year low of $45.56 and a 1-year high of $103.81. The firm has a market capitalization of $3.39 billion, a P/E ratio of -31.67 and a beta of 1.05. The firm has a 50-day simple moving average of $66.32 and a 200 day simple moving average of $78.15.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million. Analysts predict that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).